<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Galmed Pharmaceuticals Ltd — News on 6ix</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd</link>
<description>Latest news and press releases for Galmed Pharmaceuticals Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/galmed-pharmaceuticals-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835782778dffbe2df0f7eec.webp</url>
<title>Galmed Pharmaceuticals Ltd</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd</link>
</image>
<item>
<title>Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-a-collaboration-agreement-with-tel-aviv-university-to-evaluate-its-scd1-inhibitor-aramchol-as-a-targeted-therapy-for-metastatic-brain-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-a-collaboration-agreement-with-tel-aviv-university-to-evaluate-its-scd1-inhibitor-aramchol-as-a-targeted-therapy-for-metastatic-brain-cancers</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol</description>
</item>
<item>
<title>Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-the-breakthrough-development-of-a-brain-penetrating-new-formulation-of-its-scd1-inhibitor-aramchol</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-the-breakthrough-development-of-a-brain-penetrating-new-formulation-of-its-scd1-inhibitor-aramchol</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS).Galmed has</description>
</item>
<item>
<title>Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-announces-receipt-nasdaq-211500190</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-announces-receipt-nasdaq-211500190</guid>
<pubDate>Fri, 30 Jan 2026 21:15:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid pri</description>
</item>
<item>
<title>Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-acceptance-breaking-abstract-133000981</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-acceptance-breaking-abstract-133000981</guid>
<pubDate>Mon, 08 Dec 2025 13:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced the presentation of a late breaking abstract for its lead drug candidate, Aramchol at HEP-DART 2025 Meeting.</description>
</item>
<item>
<title>Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-grant-patents-combination-133000452</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-grant-patents-combination-133000452</guid>
<pubDate>Thu, 04 Dec 2025 13:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra (MGL-3196, resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH),</description>
</item>
<item>
<title>Galmed Issues CEO Letter to Shareholders</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-issues-ceo-letter-shareholders-133000389</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-issues-ceo-letter-shareholders-133000389</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer.</description>
</item>
<item>
<title>Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-reports-third-quarter-133000157</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-reports-third-quarter-133000157</guid>
<pubDate>Wed, 26 Nov 2025 13:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</description>
</item>
<item>
<title>Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-meaningful-top-line-133000990</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-meaningful-top-line-133000990</guid>
<pubDate>Tue, 18 Nov 2025 13:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced meaningful top-line results from Galmed's AM-001 Study, a Phase 1 Bioavailability (BA) Study of Aramchol meglumine.</description>
</item>
<item>
<title>Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-top-line-results-133000201</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-top-line-results-133000201</guid>
<pubDate>Mon, 17 Nov 2025 13:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today results from its joint research with Virginia Commonwealth University (VCU) evaluating Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. The collaboration is based on breakthrough findings published in Nature Communications linking Aramchol to overcome cancer drug res</description>
</item>
<item>
<title>Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-reports-second-quarter-120000049</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-reports-second-quarter-120000049</guid>
<pubDate>Thu, 28 Aug 2025 12:00:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three and six months ended June 30, 2025 and recent developments.</description>
</item>
<item>
<title>Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-digital-asset-management-113000332</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-digital-asset-management-113000332</guid>
<pubDate>Mon, 25 Aug 2025 11:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced that its Board of Directors has approved a digital asset management strategy as part of a new treasury investment policy and capital allocation initiative. To this end, the Board established a Crypto Committee of the Board, which is evaluating and, if appropriate, will oversee the im</description>
</item>
<item>
<title>Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-identifies-proprietary-biomarker-signature-120000863</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-identifies-proprietary-biomarker-signature-120000863</guid>
<pubDate>Tue, 27 May 2025 12:00:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced a major scientific and strategic milestone: the discovery of a proprietary pharmacodynamic (PD) blood-based biomarker signature for its lead candidate, Aramchol — the industry's most clinically advanced stearoyl-CoA desaturase 1 (SCD1) inhibitor.</description>
</item>
<item>
<title>Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-reports-first-quarter-120000941</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-reports-first-quarter-120000941</guid>
<pubDate>Thu, 22 May 2025 12:00:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments.</description>
</item>
<item>
<title>Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-reports-significant-anti-fibrotic-120000952</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-reports-significant-anti-fibrotic-120000952</guid>
<pubDate>Tue, 13 May 2025 12:00:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today results showing significant effects of Aramchol in pre-clinical models of primary sclerosing cholangitis (PSC).</description>
</item>
<item>
<title>Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-first-time-results-113000786</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-first-time-results-113000786</guid>
<pubDate>Tue, 06 May 2025 11:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.</description>
</item>
<item>
<title>Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-signed-term-sheet-development-120000042</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-signed-term-sheet-development-120000042</guid>
<pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it has signed a binding term-sheet with Entomus s.r.o. for a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.).</description>
</item>
<item>
<title>Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-launches-vcu-collaboration-123000870</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-pharmaceuticals-launches-vcu-collaboration-123000870</guid>
<pubDate>Thu, 17 Apr 2025 12:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company, today announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal (GI) cancers. Under the Sponsored Project Agreement, VCU scientists will study Aramchol in preclinical models of advanced GI malignancies – focusing on colorectal and hepatocellular (liver) cancers – in</description>
</item>
<item>
<title>Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-unveils-novel-pharmacodynamic-blood-123000723</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-unveils-novel-pharmacodynamic-blood-123000723</guid>
<pubDate>Tue, 15 Apr 2025 12:30:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications, today announces the unveiling of novel pharmacodynamic (PD) blood markers for its lead compound, Aramchol, the industry's most clinically advanced SCD1 inhibitor. These newly identified biomarkers shed fresh light on Aramchol's potential far beyond its role in NASH (MASH)</description>
</item>
<item>
<title>Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor</title>
<link>https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-positive-part-1-120000753</link>
<guid isPermaLink="true">https://6ix.com/company/galmed-pharmaceuticals-ltd/news/galmed-announces-positive-part-1-120000753</guid>
<pubDate>Thu, 10 Apr 2025 12:00:00 GMT</pubDate>
<description>Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.</description>
</item>
</channel>
</rss>